You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Jeff Shuren’s FDA legacy: Bringing stability to device regs
The news of Jeff Shuren‘s departure from his long-held role as head of the Food and Drug Administration’s Center for Devices and Radiological Health — which my colleague Lizzy Lawrence reported exclusively last month — has left the medical device world stunned and struggling to imagine the agency without him.
Shuren has led CDRH since 2009, with key charges of earning the medical device industry and the public’s trust. Experts say he’s been more successful with industry, including by making the regulatory labyrinth for medical devices more predictable, but not as much with the public — especially as risky products continue to slip through the cracks, like the Philips sleep apnea machines recalled in 2021.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect